

# PERKINELMER TO COMBINE WITH BIOLEGEND, ACCELERATING LEGENDARY DISCOVERIES



## Transaction Features

- Purchase price of **\$5.25B**; **\$2.2B stock consideration** with remainder from new debt and cash on hand, committed to remain investment grade
- Enhanced combined company growth and margin profile with expected **\$0.30 adj. EPS accretion in Year 1 and >\$0.50 in Year 2**
- **High single-digit adj. ROIC** anticipated by Year 6
- Expected to **close by end of 2021**

“We are thrilled to have the opportunity to bring our technologies and **innovative cultures** together to create seamless solutions to push science and discovery forward. We believe the joining of our teams poses a very exciting opportunity to **accelerate discoveries in fast growing markets** which will help life science researchers leverage ever developing technologies and novel approaches to better understand and fight disease.”



**Prahlad Singh**  
President and Chief Executive Officer,  
PerkinElmer Inc.

## BioLegend: Global Innovator of Antibodies & Reagents

**\$380M** 2022e Revenue

100% Recurring Revenue  
Accretive Margin Profile

### Revenue Split

55% North America

25% Europe & ROW

20% Asia Pacific



**>700**

Employees

**10K**

Customers

**130**

Countries



Global Reagents Center of Excellence for  
Legendary Discovery

Headquarters in San Diego, CA

## Strategic Rationale

- Further expands PKI in **fast growing markets** such as biologics, cell and gene therapy, proteogenomics, and recombinant proteins and increases PKI's overall mix of recurring and higher margin revenue
- BioLegend's **San Diego HQ to become content development engine** for life science reagents and accelerate NPIs in high-growth opportunities
- Will **increase clinical impact** by leveraging PKI's position in diagnostics and broad commercial reach
- Further **accelerates financial profile** of combined company by adding 100 bps of organic growth and 300 bps of higher operating margin

## Leading Global Player in Antibody & Research Reagents

PKI and BioLegend:  
Combined Research Portfolio

**~\$700M**

2022e Revenue

**+LDD**

Projected Growth